Anti Cancer

PTX Breast Cancer Trial Results Exceed Industry Expectations

Next Investors Archived May 17, 2018

Prescient Therapeutics (ASX:PTX) is looking to prove up its two breast cancer therapies, putting it ahead of the field in areas of high unmet need.

Rhythm Biosciences scores biomarker patents in Europe

Finfeed Archived May 16, 2018

Rhythm Biosciences (ASX:RHY) has today announced that coverage of its granted European patent (EP2829881) has been confirmed in 13 jurisdictions.

Rhythm Biosciences’ antibodies pass latest round of tests

Finfeed Archived May 14, 2018

Rhythm Biosciences (ASX:RHY) has completed the first phase development of two new antibody reagents.

Prescient reports blockbuster results in breast cancer

Finfeed Archived Apr 10, 2018

Clinical-stage oncology company Prescient Therapeutics Ltd (ASX:PTX) has today announced its most significant clinical milestone to date — the highly encouraging results of its PTX-200 Phase 1b Breast Cancer trial.

The bright new world beyond traditional cancer treatments

Finfeed Archived Mar 29, 2018

ASX small-cap Prescient Therapeutics (PTX) is bringing two novel cancer drugs to the table; PTX-200 to treat breast cancer, ovarian cancer and acute myeloid leukaemia (AML), and PTX-100 to treat a range of solid and blood cancers.

PharmAust teams up with leading cancer research institute on MPL drug candidate

Finfeed Archived Mar 15, 2018

PharmAust (ASX:PAA), a clinical-stage oncology company, has revealed its new collaboration with Dr Doug Fairlie, a leading cancer researcher based at Victoria’s prestigious Olivia Newton-John Cancer Research Institute (ONJCRI).

ASX Junior at the Forefront of Cancer Research Could be Set for a Blockbuster Year

Next Investors Archived Mar 13, 2018

This biotech appears to have cracked one of the holy grails of cancer research: it’s currently in human clinical trials with not one, but two innovative drugs which ‘turn off the switch’ that would otherwise allow cancerous cells to grow via the important Akt and Ras pathways.

BARD1 releases further positive results

Finfeed Archived Mar 06, 2018

BARD1 Life Sciences (ASX:BD1) has announced additional positive results from its BARD1-Ovarian test, indicating that the test returned 89% sensitivity and 82% specificity.

Pharma giant Merck bids $500M for ASX biotech Viralytics

Finfeed Archived Feb 23, 2018

Merck & Co (NYSE:MRK), one of the largest pharmaceutical companies in the world, has bid A$502 million for ASX-listed Viralytics (ASX:VLA) — a deal that would secure the rights to VLA’s lead immunotherapy cancer drug, Cavatak.

BD1 secures Japanese patent towards cancer treatments

Finfeed Archived Feb 02, 2018

Biotech play BARD1 Life Sciences Limited (ASX:BD1) today announced that it has received a Japanese patent for its BARD1 isoforms.

BARD1 announces positive results from ovarian cancer test

Finfeed Archived Jan 10, 2018

BARD1 Life Sciences Limited (ASX:BD1) has received positive results from its OC-400 Study that showed BARD1-Ovarian achieved high accuracy for detection of ovarian cancer.

Immuno-oncology: a new horizon in the fight against cancer

Finfeed Archived Oct 03, 2017

While a diagnosis of cancer is still likely to strike fear into the heart of any patient and their loved ones, treatments for the horrible disease are progressing – and for many cancers, survival rates are steadily heading in the right direction.

Is IMU on the path to a viable cure for cancer?

Finfeed Archived Sep 26, 2017

MitchelLake’s Robin Block spoke with Leslie Chong, the CEO of Imugene, to find out how technology is changing biotech, and how it is transforming the general understanding of cancer treatment.

IMU Picks up the Pace in Cancer Drug Treatment Development

Next Investors Archived Aug 09, 2017

It is difficult to understate the possible impact of the immuno-oncology therapies that the $33 million-capped Imugene (ASX: IMU) is currently developing. These therapies, if proven safe and successful, could have an undeniable real world positive effect for cancer patients.

BD1 gets Australian patent for cancer-related tech

Finfeed Archived Aug 07, 2017

BARD1 Life Sciences (ASX: BD1), a company focused on developing and commercialising non-invasive diagnostic tests for early detection of cancer, has gained patent approval from IP Australia for its “BARD1 isoforms in lung and colorectal cancer and use thereof”.

Ground breaking win for cancer patients

Finfeed Archived Jul 31, 2017

Until now, a one off treatment of Opdivo would cost A$5,000, or over A$100,000 per year. Thanks to the Federal Government, it will now be available for just A$38.80 per treatment, or A$6.30 with a concession card.

Merger and acquisition activity heightens in healthcare sector

Finfeed Archived Jun 16, 2017

Shares in cancer immunotherapy drug developer, Imugene (ASX: IMU) rallied more than 7% on Thursday while the S&P/ASX All Ordinaries index plunged 65.5 points or 1.1%.

Will Imugene’s expertise in immunotherapies result in an AstraZeneca type rerating?

Finfeed Archived May 17, 2017

On May 12, global pharmaceutical group and leading drug developer, AstraZeneca (LON: AZN) announced positive top-line results for the Phase III PACIFIC trial as Imfinzi demonstrated superior progression-free survival (PFS) in ‘all-comer’ patients with locally-advanced, unresectable non-small cell lung cancer (NSCLC), making it the first immuno-oncology medicine to show superior PFS in this setting. The

< prev Page 4 of 6 next >